
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics Inc. demonstrates a positive growth trajectory, with its revenue reaching $2.62 billion, representing a year-over-year increase of 14.5% and organic growth of approximately 5%. The company's consumer-initiated testing segment is particularly strong, posting nearly $60 million in revenue for the fourth quarter alone and contributing to almost $100 million in total revenue, with the introduction of approximately 135 new tests. Additionally, management anticipates an expansion of operating margins in 2025 and has projected robust cash flow from operations of $1.45 billion, suggesting ongoing financial stability and capacity for capital deployment.
Bears say
Quest Diagnostics Inc is facing several financial headwinds that contribute to a negative outlook for the company's stock. Key factors include an approximate $0.20 per share impact related to investments in modernizing its IT infrastructure and compliance with Laboratory Developed Test (LDT) regulations, as well as a $0.50 per share impact from increased year-over-year interest expenses. Additionally, despite a potential ongoing tailwind from its advanced diagnostics menu, the mixed hospital backdrop suggests challenges in market demand that could further dampen revenue growth.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares